MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $132.16M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 1.67M
Average 0.95M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -9.3% | +25.3% (4yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -9.3% over three years. Forward estimates point to Revenue at +25.3% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Anteris Technologies Global Corp. NASDAQ:AVR | $528.22M | $5.42 | Not rated | -2.3 | +50.59% |
Prenetics Global Limited NASDAQ:PRE | $279.64M | $16.51 | Undervalued | -4.9 | -19.95% |
Profound Medical Corp. NASDAQ:PROF | $271.77M | $7.42 | Not rated | -6.3 | +12.07% |
TriSalus Life Sciences, Inc. NASDAQ:TLSI | $149.93M | $2.43 | Not rated | -7.4 | -56.15% |
Armata Pharmaceuticals, Inc. AMEX:ARMP | $143.89M | $3.87 | Not rated | -0.9 | -58.32% |
Perspective Therapeutics, Inc. AMEX:CATX | $113.89M | $0.94 | Not rated | -0.0 | -63.02% |
Owlet, Inc. NYSE:OWLT | $100.52M | $3.44 | Not rated | -0.4 | -72.99% |
LENSAR, Inc. NASDAQ:LNSR | $61.47M | $5.00 | Not rated | 2.4 | -52.16% |
Sangamo Therapeutics, Inc. NASDAQ:SGMO | $30.66M | $0.07 | Not rated | -0.5 | -54.55% |
Nano-X Imaging Ltd. NASDAQ:NNOX | $25.36M | $0.32 | Not rated | -1.5 | -78.79% |
Continue the stock analysis
Jump to another research area for this company.